SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants

Mar 6, 2018

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Mar 5, 2018

SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018

Feb 1, 2018

SCYNEXIS Provides Corporate and SCY-078 Pipeline Update

Jan 4, 2018